FASTER, PLEASE: Lymphoma vaccine extends survival in late-stage study. “In a study published in the online version of the Journal of Clinical Oncology, researchers at the University of Texas MD Anderson Cancer Center say a Phase III trial of the therapeutic vaccine BioVaxID for follicular lymphoma increased disease-free survival by 14 months.”
InstaPundit is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.